Zefacet is an approved prescription medication used to address certain bacterial infections in adults and pediatric patients six months of age and older. Its purpose is to support the body's recovery by targeting susceptible bacteria that cause illness.

---

Quick Facts

• Supports the management of bacterial infections in specific areas of the body.
• Used for conditions involving the middle ear (otitis media).
• Indicated for infections of the throat and tonsils (pharyngitis and tonsillitis).
• Provides assistance in treating acute exacerbations of chronic bronchitis.
• Utilized for uncomplicated infections of the urinary tract.

---

The therapeutic domain for this medication includes the management of uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis. It is also utilized for otitis media (middle ear infections) and pharyngitis and tonsillitis when caused by susceptible bacterial isolates. Additionally, Zefacet is indicated for addressing acute exacerbations of chronic bronchitis and certain forms of uncomplicated gonorrhea.

Administration of the medication is intended to provide a pathway toward clinical improvement and resolution of symptoms associated with these infections. It is a therapeutic choice that may be utilized when these conditions are strongly suspected or proven to be caused by susceptible bacteria.

The eligibility for using Zefacet is strictly governed by population-specific restrictions defined in official regulatory labeling. Contraindication exists for individuals with a known allergy to Cefixime, other cephalosporins, or a history of severe hypersensitivity to any beta-lactam antibiotic such as penicillin.

Approved and Restricted Populations

The medicine is approved for adults and pediatric patients six months of age and older. Efficacy and safety have not been established for infants younger than six months.

Use is conditional in several groups:

• Renal Impairment: Patients with reduced kidney function require dosage adjustment when creatinine clearance is less than 60 mL/min.
• Pregnancy/Lactation: Use during pregnancy is recommended only if clearly needed. For nursing mothers, regulatory documents advise considering the temporary discontinuation of nursing.
• Comorbidity: Patients with Phenylketonuria (PKU) should be restricted from using the chewable tablet formulation due to its phenylalanine content.

The interaction profile of Zefacet (Cefixime) is defined by documented effects on the clearance of co-administered drugs and alterations to specific physiological and diagnostic parameters, as reported in regulatory documentation.

Official Interaction Statements

Classification	Details (Official Regulatory Information Only)
Pharmacodynamic Interactions	Co-administration with Warfarin and other anticoagulants is associated with an increased prothrombin time ( PT) and a potential for bleeding events. This requires attention to the patient’s coagulation status.
Exposure-Altering Interactions	Elevated plasma levels of Carbamazepine have been reported when this medicine is used concomitantly with Cefixime.
Altered Cefixime Clearance	Probenecid and Nifedipine are stated to increase the systemic exposure (plasma concentrations and AUC) of Cefixime by inhibiting its renal clearance.
Effectiveness Modification	The effectiveness of oral hormonal contraceptives may be decreased due to an interaction that alters intestinal bacterial flora.
Food Interaction	Administration of the Cefixime oral suspension with food is documented to delay the time to reach peak Cefixime concentration ( T max), but the overall amount absorbed is not significantly affected.
Diagnostic Interference	Cefixime may cause false-positive reactions for glucose in the urine when tests use non-enzymatic methods (e.g., Benedict's solution). It may also result in false-positive results for the Direct Coombs' test and specific urine ketone tests that utilize nitroprusside.

Population-Specific Interaction Note

Patients with impaired renal function exhibit reduced clearance of Cefixime, leading to increased systemic drug exposure. This is a population-specific pharmacokinetic constraint that requires consideration.

How Zefacet Works

Zefacet's action targets the protective structure of susceptible bacteria by interfering with their cell-building enzymes. This mechanism results in a bactericidal effect.

---

Irreversible Blockade of Cell Wall Construction

This mechanism addresses the drug's core molecular action: the active ingredient, Cefixime, functions as an irreversible inhibitor of bacterial Penicillin-Binding Proteins (PBPs). By covalently binding to these D,D-transpeptidases, the drug blocks the final crucial step of peptidoglycan cross-linking, which is necessary for establishing the rigid structural integrity of the bacterial cell wall.

---

The Mechanism of Osmotic Cell Lysis

The consequence of the blockade is the disruption of bacterial cell homeostasis as the weakened cell wall can no longer withstand the high internal osmotic pressure. This imbalance causes the influx of fluid, leading to the rapid and complete rupture of the bacterial cell (lysis). This destructive cellular outcome is the direct physiological effect that constitutes the drug’s bactericidal activity against target pathogens.

The administration of Zefacet (Cefixime) is via the oral route for all available forms, which include tablets, capsules, and oral suspension. The standard approach for adult patients involves administering a total of 400 mg per day. This quantity may be taken as a single dose once daily, or it can be divided into 200 mg doses taken every 12 hours. This pattern of frequency allows for a flexible regimen.

---

Administration Requirements

The medication may generally be taken without regard to food for capsule and tablet forms. However, specific rules govern the preparation and intake of different forms. The powder intended for oral suspension must be reconstituted with water and must be shaken well before each use to ensure proper dosage. The reconstituted suspension is subject to a time constraint and must be discarded after 14 days.

---

Dosing Adjustments and Duration

Dosing is adjusted based on patient population and renal function. For children aged six months and older, the prescribed amount is based on body weight, typically 8 mg/kg/day. Adults with impaired kidney function require a dose reduction if their Creatinine Clearance is below 60 mL/min. For infections caused by Streptococcus pyogenes, the medication is administered for a minimum course of ten days. Furthermore, tablets or capsules should not be substituted for the oral suspension when treating middle ear infections due to differences in drug absorption.

Research Evidence / Overview of Studies for Zefacet

Research Landscape and Types of Clinical Studies

The clinical evidence for Zefacet, whose active ingredient is Cefixime, was studied for how it affects conditions associated with acute or disruptive episodes. The core research approach involved Randomized Controlled Trials (RCTs) and comparative studies, where researchers assigned participants by chance to different treatment groups to examine outcomes measured by clinical response and pathogen presence.

In these research settings, investigators monitored key measurements: the change in a patient's symptoms (known as clinical response) and the complete clearance of the specific bacteria causing the illness (bacteriological eradication). The evidence contributes to understanding symptom patterns over defined time intervals, providing context but not individual predictions about whether a patient will respond similarly.

Evidence for use in Uncomplicated Urinary Tract Infections (UTI)

For uncomplicated UTIs caused by specific susceptible organisms like E. coli and P. mirabilis, Cefixime was evaluated in short-term clinical trials. These studies primarily included adults and pediatric patients (6 months and older). Researchers monitored outcomes related to physical discomfort during periods of increased symptom activity.

The studies describe patterns observed in how symptoms were monitored during the short treatment course (often 3 to 7 days) and at a follow-up visit a few weeks later. However, follow-up durations were limited, meaning there is limited information for long-term outcomes regarding the recurrence of infection. Evidence quality varies across studies, particularly when defining key measures like "clinical cure."

Evidence for use in Acute Otitis Media (AOM) and Pharyngitis/Tonsillitis

Research exploring short-term symptom changes in middle ear infections (AOM) and throat infections (pharyngitis/tonsillitis) often involved RCTs and multicenter studies. Cefixime was observed in trials that utilized the oral suspension form, which is frequently given to pediatric patients.

For these conditions characterized by fluctuating manifestations, studies focused on monitoring the overall clinical response and bacteriological eradication. For pharyngitis caused by S. pyogenes, trials monitored the clearance of bacteria. Regulatory guidance notes that data establishing the prevention of complications like rheumatic fever are unavailable.

Research Gaps and Unanswered Questions

While research has explored the short-term effects of Cefixime, certainty remains low in several key areas. Comparative evidence is lacking in some areas, and researchers continue to seek data to fill in these gaps. Additionally, research does not determine how an individual will respond, as findings describe group patterns, not personal outcomes. The ongoing challenge of bacterial resistance means continuous research is ongoing to monitor changes in bacterial susceptibility to Cefixime.

Common questions about Zefacet (FAQ)

Q: Are there other brand names for Zefacet?

A: The active ingredient in Zefacet, Cefixime, is sold under various trade names globally. One commonly known brand name for the Cefixime entity is Suprax.

Q: How is Zefacet different from [Drug X]?

A: Zefacet is an antibiotic belonging to a specific group known as third-generation cephalosporins. According to official documents, its action involves the final step of bacterial cell wall formation, which leads to the loss of structural integrity of the bacterial organism.

Q: Will Zefacet make me feel drowsy or tired?

A: Official information on reported side effects indicates that some patients have experienced reactions such as dizziness and drowsiness. These central nervous system effects are generally uncommon compared to the most frequently reported adverse reactions.

Q: Can Zefacet affect my ability to drive or operate machines?

A: Because of the potential for certain side effects, including dizziness, confusion, or in rare cases, seizures (referred to as fits in some official documents), caution is generally advised. Official safety documents contain directions regarding the restriction or careful use of vehicles or machinery due to these potential effects.

Q: Can Zefacet be split or crushed?

A: Official administration instructions state that the tablet form may be split or cut to divide the dose. The regulatory guidelines for the capsule form, however, specify that it is intended to be swallowed whole.

Q: What if I accidentally miss a dose of Zefacet?

A: If a dose is missed, official patient instructions advise taking it as soon as it is remembered. However, if it is almost time for your next dose, the instruction is to skip the missed dose and resume the normal schedule. Official instructions specify that an extra dose should not be taken to make up for the missed amount.

Q: Does Zefacet affect blood sugar levels?

A: Zefacet may interfere with specific laboratory tests. Official documents state that the medicine can cause false-positive results for glucose (sugar) in the urine when tested using older, non-enzymatic methods. This is an artifact of the testing process and is not a statement about the physiological change in blood sugar levels.

Q: Can I take Zefacet with pain relievers like paracetamol/acetaminophen?

A: Based on official drug interaction information, no known interaction has been reported between Cefixime, the active ingredient in Zefacet, and Paracetamol (also called Acetaminophen).

Q: Why is Zefacet only available with a prescription?

A: Regulatory bodies classify Zefacet as a prescription-only medicine. This requirement is in place to ensure that the drug is used appropriately only when a bacterial infection is strongly suspected, a practice that is important for reducing the risk of developing antibiotic-resistant bacteria.

Q: Is Zefacet safe for older people, like those over 65?

A: Regulatory documents have not reported specific problems unique to the general elderly population for Zefacet use. However, because reduced kidney function is common in older adults, a dose adjustment may be required in cases where impaired kidney function is present.

Q: How long does it usually take for Zefacet to start working?

A: According to official patient information, a patient using Zefacet may begin to notice an improvement in their symptoms within the first few days of starting the treatment.

Q: Why do doctors prescribe Zefacet for different conditions?

A: The medicine is prescribed for multiple conditions because it is effective against a range of susceptible bacteria. Official regulatory indications include various urinary tract infections, middle ear infections (Otitis Media), and certain upper and lower respiratory infections.

Q: Does Zefacet have a risk of addiction?

A: Zefacet is classified by regulatory authorities as Not a controlled substance. Its pharmacological class, cephalosporin antibiotics, is not associated with any risk of addiction or dependence.

Q: What should I do if I think Zefacet is not working for me?

A: Patient guidance indicates that if you notice your symptoms do not improve or begin to worsen after you have started taking the medicine, contact with the prescribing healthcare provider is advised for further guidance.

Q: Is Zefacet generally considered a short-term or long-term medication?

A: Zefacet is primarily used as an antibiotic for the short-term treatment of specific acute bacterial infections. The length of time you take the medicine is determined by the specific infection, with many courses lasting up to ten days.

Q: Is Zefacet known to cause mood changes or depression?

A: While depression and common mood changes are not typically listed, regulatory documents report that less common central nervous system effects such as confusion, dizziness, anxiety, and irritability have been experienced by some patients.

Q: What is the scientific evidence supporting the use of Zefacet?

A: The evidence supporting the approved uses of Zefacet comes primarily from Randomized Controlled Trials (RCTs). These clinical studies measured key outcomes such as the patient’s clinical response and the eradication of the targeted bacteria within the specific, approved infection areas.

Q: Is it possible to be allergic to Zefacet?

A: Yes, the possibility of an allergic reaction exists. Official warnings list the potential for serious hypersensitivity reactions, including anaphylaxis. The drug is contraindicated for patients who have a known allergy to Cefixime or other antibiotics in the penicillin or cephalosporin class.

Q: Is Zefacet used to treat arthritis or inflammation?

A: The official indications for Zefacet are strictly for the treatment of bacterial infections. It is not indicated or approved by regulatory bodies for use in treating conditions such as arthritis or general non-bacterial inflammation.

Q: Can Zefacet change the color of my urine or stool?

A: Adverse reaction reports indicate that less common side effects have included changes to body waste appearance. These changes may include observations of dark or clay-colored stools or red or dark brown urine.

Q: Are there any special warnings about Zefacet for people with liver issues?

A: Official warnings state that Zefacet may cause abnormal liver enzyme test results. Patients with pre-existing liver disease require special consideration, as this condition can affect how the medicine is managed.

Q: Is Zefacet a controlled substance?

A: Zefacet is classified by regulatory authorities as Not a controlled substance. It is not listed in the official DEA Schedules for controlled medications.

Storage and Stability Requirements

Official regulatory documents define specific storage rules for Zefacet (Cefixime) based on its form:

• Dry Powder: The powder for oral suspension must be stored at temperatures that do not exceed 30°C.
• Solid Forms: Tablets and capsules require storage at controlled room temperature.

Once the oral suspension is mixed (reconstituted), the stability period begins. The reconstituted liquid is stable for up to 14 days when stored either at room temperature (15°C to 25°C) or under refrigeration (2°C to 8°C). The official labeling prohibits freezing the reconstituted suspension, and the container must be kept tightly closed and shaken well before each use. Any unused portion must be discarded after 14 days.

Disposal and Child Safety

All medicines must be kept out of the sight and reach of children. Disposal of expired or unused Zefacet should be done in accordance with local requirements for pharmaceutical waste.